TrialCancer medicine2015

Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute.

John D Hainsworth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.